Vir Biotechnology’s program reported that monthly injections of two experimental medicines reduced hepatitis D virus to undetectable levels in 44% of patients in a Phase 3 study objective. The result came in a regimen comparison against delayed treatment with the same monthly dosing approach. The update targets a difficult-to-treat viral population with limited durable eradication options, keeping attention on combination antiviral strategies designed to suppress HBV/HDV-linked disease trajectories.